Navigation Links
'De-Tangling' Alzheimer's Drug Shows Promise
Date:7/29/2008

Patients' cognition improved as medication rid brain of matted protein, researchers say

TUESDAY, July 29 (HealthDay News) -- A drug that aims to reduce the clogging "tangles" in the brain cells of people with Alzheimer's disease appears promising in early trials, researchers report.

Further studies are necessary to confirm whether the medication is as effective at slowing Alzheimer's as it seems, or whether it needs to be given as part of a cocktail of treatments.

Still, the new findings are promising, said study lead author Claude M. Wischik, professor in mental health at the University of Aberdeen in the U.K., and chairman of TauRx Therapeutics, which is testing the compound. "The good news is that this is a breakthrough," he said. "A whole new, different approach has opened up against the odds, against people's expectations."

These and other findings into potential Alzheimer's treatments were expected to be released Tuesday at the Alzheimer's Association's International Conference on Alzheimer's Disease, in Chicago.

At issue in the TauRx study are proteins in the brain known as tau. If they work correctly, they act as the equivalent of rivets in the "railroad tracks" in brain cells, allowing communication between cells, Wischik said.

But in people with Alzheimer's disease, these proteins create untidy mats of fibers called "tangles" in the brain. The tangles are directly linked to dementia, while the effects of another factor in Alzheimer's -- bits of protein gunk called amyloid plaques -- are variable, he said.

"People could have lots of this stuff (amyloid) and still play lots of bridge," Wischik said, "but if you have a lot of aggregated tau in the brain, you can't find your way to the toilet."

The new study looked at a drug designed to reduce the number of tangles. The study was a Phase II trial, meaning it looked only at appropriate doses and effectiveness. A larger, Phase III trial -- the last of the three routine phases of research into a drug -- is scheduled to begin next year.

Researchers gave either the drug, known as MTC, or a placebo to 321 Alzheimer's patients in the United Kingdom and in Singapore for 24 weeks.

Wischik's group found that the drug stabilized the progression of Alzheimer's over 50 weeks.

"The data show an 82 percent of reduction in the rate which the disease progresses," Wischik said.

Dr. Sam Gandy, chairman of the Alzheimer's Association's National Medical and Scientific Advisory Council, said the new study results are indeed promising, and he added that another anti-tau treatment is in the works.

"They could potentially be part of a cocktail of anti-amyloid and anti-tau drugs that might be the way we eventually come around to treating Alzheimer's, trying to hit multiple steps (in disease formation)," he said. "This is the sort of approach that's been successful in treating HIV and cancer."

The finding comes on the heels of results from another tau-targeted Alzheimer's drug trial, released at the ICAD meeting Monday. In that study, led by Dr. Donald Schmechel of Duke University Medical Center, older adults with what's known as mild cognitive impairment received an experiment nasal spray peptide called AL-108.

Mild cognitive impairment is typically thought of as a potential precursor to Alzheimer's disease. In the Phase II study, patients who received high doses of AL-108 over 12 weeks gained "statistically significant, dose-dependent and durable improvement" in a variety of memory abilities, Schmechel said in an Alzheimer's Association news release.

In other findings released at the meeting Tuesday:

Researchers released detailed results of a Phase III trial of the drug tarenflurbil (Flurizan), which was targeted at reducing the sticky amyloid plaques in the brain. In June, the drug's manufacturer, Myriad Genetics, announced that the agent had failed to effectively treat Alzheimer's disease. The company is no longer developing the drug for the treatment of Alzheimer's.

According to the results of the trial, the drug did reduce plaques but was still no better at helping patients with mild Alzheimer's than a placebo, while causing more of some types of side effects.

On the other hand, a Phase II trial of a drug known as PBT2 did show some promising results. According to researchers at the University of California, Los Angeles, PBT2 is thought to reduce amyloid plaques by disrupting the interaction of chemicals in the brain.

The trial, which was also published online Tuesday in The Lancet Neurology, involved 78 people with mild Alzheimer's who got PBT2 or a placebo daily for 12 weeks. The agent did reduce levels of amyloid plaque in cerebrospinal fluid. People on the higher dose (250 milligrams) of the drug also showed significant improvements in certain mental tests compared to those on placebo, the team reported.

Finally, a study from food company Danone suggests that a nutrient-rich "medical food" called Souvenaid could help boost the formation of brain synapses and may reduce amyloid plaques in patients with mild Alzheimer's. The product contains nutrients such as choline and omega-3 fatty acids, thought to be conducive to brain health.

More information

Learn more about the disease from the Alzheimer's Association.



SOURCES: Claude M. Wischik, MB ChB, professor in mental health, University of Aberdeen, U.K., and chairman, TauRx Therapeutics, Singapore; Sam Gandy, M.D., Ph.D., chair, National Medical and Scientific Advisory Council, Alzheimer's Association, and professor, Alzheimer's disease research, Mount Sinai School of Medicine, New York City; Alzheimer's Association International Conference on Alzheimer's Disease, Chicago, July 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. New Research Shows Chronic Stress Worsens Neurodegenerative and Inflammatory Illnesses
3. Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment
4. Study shows emergency physicians have good first instincts in diagnosing heart attacks
5. Cranberry juice creates energy barrier that keeps bacteria away from cells, study shows
6. New Study Shows Facial Plastic Surgery Helps African American's Perserve Ethnicity
7. Corneal transplant technique shows promise in children
8. Reading, math scores up for 4th and 8th graders, federal report shows
9. Teen Birth Rates, Homicides on Increase, Report Shows
10. Cancer drug shows promise against graft vs. host disease
11. New Research Shows Cadaver Tissue Fails Nearly a Quarter of the Time in Young, Athletic ACL Reconstruction Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'De-Tangling' Alzheimer's Drug Shows Promise
(Date:4/27/2017)... Neb. (PRWEB) , ... April 27, 2017 , ... ... was named the 2017 North American CAREGiverSM of the Year for her extraordinary ... selects one of its 60,000 North American professional caregivers for the prestigious award ...
(Date:4/27/2017)... ... 2017 , ... Are you investing in the safety of your friends and ... the summer. While most of us assume this type of accident will never happen ... people are taking the time to learn how to respond effectively or prevent these ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Journal ... adults. It can have severe consequences to overall dental health, including complications with speech, ... often turn to dental implants to replace lost teeth. As the number of tooth ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and ... by Enterprising Women magazine as one of its 2017 Enterprising Women of the ... Winners have demonstrated that they have fast-growth businesses, mentor or actively support other ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy ... get nutrients from SUPERFOODS! , RawTrition is taking nutrients to the next ... because the body recognizes its raw form (unlike the synthetically made options that are ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
Breaking Medicine Technology: